SEC Form 4 · accession 0001209191-15-064718
SURMODICS INC · SRDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles W Olson
Officer — Senior VP & GM, Med Dev
Period of report
Aug 5, 2015
Accepted (ET)
Aug 7, 2015 · 6:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000924717
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 5, 2015 | S | 5,000 | $26.0733 | D | 24,390 | D | |
| Common Stock | Aug 5, 2015 | S | 5,000 | $26.25 | D | 19,390 | D | |
| Common Stock | holding | — | — | — | 800 | I | By IRA |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2015.
- F2Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on August 5, 2015 with sale prices ranging from $25.94 to $26.11 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.